2025-10-11 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX), incorporating the provided data.

## TG Therapeutics Inc. (TGTX) Analysis

**0. Executive Summary:**

TGTX, a biopharmaceutical company focused on developing treatments for B-cell malignancies and autoimmune diseases, shows a mixed picture. While recent news and analyst opinions are generally positive, indicating confidence in their multiple sclerosis drug Briumvi, financial performance and historical stock performance present some concerns. It is essential to review the companyâ€™s performance for a longer duration.

**1. Relative Performance:**

*   **Ticker:** TGTX
*   **Company:** TG Therapeutics Inc.
*   **Description:** A biopharmaceutical company focused on developing treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 79.33%
*   **S&P 500 (VOO) Cumulative Return:** 99.08%
*   **Absolute Divergence (TGTX - VOO):** -11.0
*   **Divergence Range (Max: 305.5, Min: -101.0):**
*   **Relative Divergence:** 22.1

**Analysis:** TGTX has underperformed the S&P 500, with a cumulative return lagging by approximately 11%. The relative divergence of 22.1 indicates that TGTX is currently in the lower end of its historical performance range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta    | Cap(B) |
| ---------- | ------- | ------ | ------- | ------- | ------ |
| 2015-2017  | -5.0%   | 73.5%  | -33.0%  | -0.0    | 1.3    |
| 2016-2018  | -12.0%  | 73.5%  | -27.0%  | -0.0    | 0.7    |
| 2017-2019  | 74.0%   | 74.1%  | 52.0%   | 0.0     | 1.8    |
| 2018-2020  | 316.0%  | 74.1%  | 293.0%  | 0.1     | 8.2    |
| 2019-2021  | 124.0%  | 74.1%  | 78.0%   | 0.3     | 3.0    |
| 2020-2022  | -71.0%  | 77.8%  | -71.0%  | -0.0    | 1.9    |
| 2021-2023  | -284.0% | 77.8%  | -285.0% | -1.1    | 2.7    |
| 2022-2024  | 56.0%   | 77.8%  | 36.0%   | -1.0    | 4.8    |
| 2023-2025  | 80.0%   | 74.8%  | 16.0%   | -0.1    | 5.4    |

*   **CAGR:** Highly volatile, with periods of significant gains and losses.
*   **MDD:** Consistently high Maximum Drawdown indicates significant risk.
*   **Alpha:** Fluctuates significantly, reflecting periods of outperformance and underperformance relative to the market.
*   **Beta:** Generally low, suggesting the stock is less sensitive to market movements. However, the negative betas in recent years are concerning, suggesting inverse correlation with the market.
*   **Cap(B):** The market cap has been growing over the years, suggesting the company is expanding and the market recognizes the potential of the company.

**2. Recent Price Action:**

*   **Current Price:** 33.99
*   **Previous Close:** 34.97
*   **Change:** -2.8%
*   **5-Day Moving Average:** 35.94
*   **20-Day Moving Average:** 34.73
*   **60-Day Moving Average:** 32.57

**Analysis:** The stock price has declined recently, falling below the 5-day and 20-day moving averages, but it remains above the 60-day moving average. The -2.8% change from the previous close indicates a short-term downward trend.

**3. Technical Indicators and Outlook:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 58.33 (Neutral, neither overbought nor oversold)
*   **PPO:** -0.48 (Slightly bearish, suggesting short-term weakness)
*   **Hybrid Signal:** Buy 100% (27 shares)
*   **Delta Previous Relative Divergence:** -1.4 (Short-term decrease in relative performance)
*   **Expected Return:** -101.6% (Significantly negative, indicating potential underperformance compared to the S&P 500 over the long term)

**Analysis:** The MRI suggests a high investment recommendation, which is interesting given the other indicators. The RSI is neutral. The PPO indicates slight bearishness. The delta previous relative divergence confirms a recent short-term decline. The significantly negative expected return is a major concern. The price decrease of -2.8% from the previous close indicates potential volatility.

**4. Recent News & Significant Events:**

*   **Positive News:** Multiple articles highlight positive six-year safety and efficacy data for Briumvi in treating multiple sclerosis. Institutional investors have been rewarded, and the drug shows a high percentage of patients free from disability progression.
*   **Neuraxpharm Participation:** Indicates ongoing commitment to multiple sclerosis treatments.

**Analysis:** Recent news is overwhelmingly positive, centered on Briumvi's long-term data and market recognition. This positive news could be a catalyst for future growth, but it contrasts with the negative expected return suggested by the historical data.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.78)
*   **Opinions:** 7
*   **Target Price:** 43.57 (Average) / 60.00 (High) / 11.00 (Low)

**Analysis:** Analyst consensus is strongly positive, with a "Buy" rating and a significant average target price of $43.57, offering substantial upside potential. However, the wide range between high and low target prices ($60.00 vs. $11.00) indicates uncertainty.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
| ---------- | ---- | ------------ |
| 2025-08-08 | 0.19 | 0.14 B$      |
| 2025-05-09 | 0.03 | 0.12 B$      |
| 2024-11-07 | 0.03 | 0.08 B$      |
| 2024-08-09 | 0.05 | 0.07 B$      |
| 2025-08-08 | 0.05 | 0.07 B$      |

**Analysis:** The recent EPS and revenue figures show improvement, with a notable increase in both EPS and revenue in the latest quarter (2025-08-08). This positive trend is encouraging.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | \$0.14B   | 86.58%        |
| 2025-03-31 | \$0.12B   | 87.14%        |
| 2024-12-31 | \$0.11B   | 85.77%        |
| 2024-09-30 | \$0.08B   | 88.86%        |
| 2024-06-30 | \$0.07B   | 88.70%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
| ---------- | --------- | -------- |
| 2025-06-30 | \$0.28B   | 10.20%   |
| 2025-03-31 | \$0.24B   | 2.13%    |
| 2024-12-31 | \$0.22B   | 10.49%   |
| 2024-09-30 | \$0.19B   | 2.02%    |
| 2024-06-30 | \$0.18B   | 3.87%    |

**Analysis:** Revenue is trending upward, and profit margins are consistently high, indicating strong operational efficiency. Equity is also increasing, but ROE is volatile, showing fluctuations in profitability.

**7. Comprehensive Summary**

TGTX presents a mixed investment profile. Recent financial results, particularly revenue and profit margins, demonstrate positive momentum. Analyst consensus is bullish, supported by promising clinical data for Briumvi, which could drive future growth. However, the stock has underperformed the S&P 500, and historical data shows high volatility and a negative expected return, suggesting significant risks. The MRI suggests a high investment recommendation, contrasting with the negative expected return. Investors should carefully weigh the potential upside from Briumvi against the stock's historical volatility and underperformance. Consider risk tolerance and perform thorough due diligence before making any investment decisions.
